SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation

Published:2020 Issue:1 Volume:67 Page:99-106
ISSN:0918-8959
Container-title:Endocrine Journal
language:en
Short-container-title:Endocr J

Author:

Komatsu Shiho¹,Nomiyama Takashi¹²,Numata Tomohiro³,Kawanami Takako¹,Hamaguchi Yuriko¹,Iwaya Chikayo⁴,Horikawa Tsuyoshi¹,Fujimura-Tanaka Yuki¹,Hamanoue Nobuya¹,Motonaga Ryoko¹,Tanabe Makito¹,Inoue Ryuji³,Yanase Toshihiko²⁴,Kawanami Daiji¹

Affiliation:

1. Department of Endocrinology and Diabetes Mellitus, School of Medicine, Fukuoka University, Fukuoka, Japan

2. Research Institute for Islet Biology, Fukuoka University, Fukuoka, Japan

3. Department of Physiology, School of Medicine, Fukuoka University, Fukuoka, Japan

4. Muta Hospital, Fukuoka, Japan

Publisher

Japan Endocrine Society

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.jstage.jst.go.jp/article/endocrj/67/1/67_EJ19-0428/_pdf

Reference20 articles.

1. 1 Emerging Risk Factors Collaboration, Seshasai SR, Kaptoqe S, Thompson A, Di Angelantonio E, Gao P, et al. (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364: 829–841.

2. 2 Kasuga M, Ueki K, Tajima N, Noda M, Ohashi K, et al. (2013) Report of the JDS/JCA joint committee on diabetes and cancer. Diabetol Int 4: 81–96.

3. 3 Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D (2012) Metabolic syndrome and risk of cancer: a systemic review and meta-analysis. Diabetes Care 35: 2402–2411.

4. 4 Nomiyama T, Kawanami T, Irie S, Hamaguchi Y, Terawaki Y, et al. (2014) Exendin-4, a glicagon-like peptide-1 receptor agonist, attenuates prostate cancer growth. Diabetes 63: 3891–3905.

5. 5 Iwaya C, Nomiyama T, Komatsu S, Kawanami T, Tsutsumi Y, et al. (2017) Exendin-4, a glucagonlike peptide-1 receptor agonist, attenuates breast cancer growth by inhibiting NF-kB activation. Endocrinology 158: 4218–4232.

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the anti-cancer potential of SGLT2 inhibitors in breast cancer treatment in pre-clinical and clinical studies;European Journal of Pharmacology;2024-09

2. Pharmacological targets of SGLT2 inhibition on prostate cancer mediated by circulating metabolites: a drug-target Mendelian randomization study;Frontiers in Pharmacology;2024-08-06

3. Empagliflozin demonstrates cytotoxicity and synergy with tamoxifen in ER-positive breast cancer cells: anti-proliferative and anti-survival effects;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-07-27

4. BRG1 promotes liver cancer cell proliferation and metastasis by enhancing mitochondrial function and ATP5A1 synthesis through TOMM40;Cancer Biology & Therapy;2024-07-08

5. Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists and cancer mortality. A real-world registry;Revista Española de Cardiología (English Edition);2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3